Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-BCMA-CD19 CAR-T cells
- Development stage
- Phase 2
- Lead developer
- The Affiliated Hospital of Xuzhou Medical University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Anti-BCMA-CD19 CAR-T cells are an autologous chimeric antigen receptor (CAR) T-cell therapy engineered to simultaneously target two distinct antigens: B-cell maturation antigen (BCMA) and CD19. Developed by The Affiliated Hospital of Xuzhou Medical University, this dual-targeting approach is designed to achieve a more comprehensive depletion of the B-cell lineage than single-target therapies. CD19 is a well-established marker for B cells, while BCMA is predominantly expressed on long-lived plasma cells, which are the primary source of pathogenic autoantibodies in many autoimmune conditions. By eliminating both B cells and plasma cells, the therapy aims to 'reset' the immune system in patients with refractory autoimmune diseases, including systemic lupus erythematosus (SLE), myasthenia gravis (MG), and neuromyelitis optica spectrum disorder (NMOSD).
- Other names
- BCMA-CD19 CAR-TBCMA-CD-19 CAR-TBCMA-CD 19 CAR-TCD19/BCMA CAR-Tdual-target BCMA-CD19 CAR-T cells
02
Targets
CD19 (B lymphocyte antigen CD19)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on anti-BCMA-CD19 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-BCMA-CD19 CAR-T cells.